[go: up one dir, main page]

MX2017009929A - Composiciones y métodos para metabolismo muscular mejorado. - Google Patents

Composiciones y métodos para metabolismo muscular mejorado.

Info

Publication number
MX2017009929A
MX2017009929A MX2017009929A MX2017009929A MX2017009929A MX 2017009929 A MX2017009929 A MX 2017009929A MX 2017009929 A MX2017009929 A MX 2017009929A MX 2017009929 A MX2017009929 A MX 2017009929A MX 2017009929 A MX2017009929 A MX 2017009929A
Authority
MX
Mexico
Prior art keywords
extract
methods
compositions
muscle metabolism
improved muscle
Prior art date
Application number
MX2017009929A
Other languages
English (en)
Other versions
MX384303B (es
Inventor
Feuillere Nicolas
Elizabeth Renée Fança-Berthon Pascale
Birtic Simona
Denise Falcao Leila
Charles Bily Antoine
Roller Marc
Chevalier Karl
Meyer Marjolaine
LAURENÇON Lise
Original Assignee
Naturex Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naturex Sa filed Critical Naturex Sa
Publication of MX2017009929A publication Critical patent/MX2017009929A/es
Publication of MX384303B publication Critical patent/MX384303B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición para mejorar el metabolismo muscular en un sujeto y métodos para su fabricación y utilización. Las modalidades incluyen composiciones con un extracto de Rhaponticum y un extracto de Rhodiola. Un extracto de Rhaponticum puede incluir cantidades de ecdisteronas que incluyen 20-hidroxiecdisona. Un extracto de Rhodiola puede incluir salidrosidas y rosavinas, que incluyen rosavina. Las dosificaciones de ingesta adecuadas de la composición pueden funcionar para aumentar la síntesis de proteínas y reducir la proteólisis de proteína en un sujeto.
MX2017009929A 2015-02-03 2016-02-03 Composiciones y métodos para metabolismo muscular mejorado. MX384303B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/612,973 US9700589B2 (en) 2015-02-03 2015-02-03 Compositions and methods for improved muscle metabolism
PCT/IB2016/000322 WO2016125025A1 (en) 2015-02-03 2016-02-03 Compositions and methods for improved muscle metabolism

Publications (2)

Publication Number Publication Date
MX2017009929A true MX2017009929A (es) 2018-04-10
MX384303B MX384303B (es) 2025-03-12

Family

ID=55806552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009929A MX384303B (es) 2015-02-03 2016-02-03 Composiciones y métodos para metabolismo muscular mejorado.

Country Status (12)

Country Link
US (2) US9700589B2 (es)
EP (1) EP3253399B1 (es)
JP (1) JP6726196B2 (es)
KR (1) KR102520312B1 (es)
CN (1) CN107624069A (es)
AU (1) AU2016214079B2 (es)
BR (1) BR112017016497B1 (es)
CA (1) CA2975497C (es)
CO (1) CO2017007874A2 (es)
MX (1) MX384303B (es)
RU (1) RU2730853C2 (es)
WO (1) WO2016125025A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3065644B1 (fr) * 2017-04-28 2020-02-21 Biophytis Extrait de 20-hydroxyecdysone de qualite pharmaceutique, son utilisation et sa preparation
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
FR3093640B1 (fr) 2019-03-15 2021-10-01 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires
CN113367337B (zh) * 2020-03-10 2023-02-24 晨光生物科技集团股份有限公司 一种包含槲皮万寿菊素的组合物
WO2025215177A1 (en) * 2024-04-11 2025-10-16 Anjac Composition for increasing muscle mass

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000781C1 (ru) * 1992-04-29 1993-10-15 Научно-производственное объединение "Алтай" Лосьон дл кожи лица
RU2066963C1 (ru) 1993-10-20 1996-09-27 Рошен Джафарович Сейфулла Натуральный поливитаминный комплекс "леветон"
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
RU2174397C1 (ru) 2000-06-02 2001-10-10 Институт нефтехимии и катализа АН республики Башкортостан и Уфимского научного центра РАН Способ получения концентрата экдистероидов и экдистерона из растительного сырья
RU2259840C2 (ru) * 2003-11-14 2005-09-10 Институт общей и экспериментальной биологии СО РАН Лекарственное средство, обладающее адаптогенной активностью
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
RU2321420C1 (ru) * 2006-07-20 2008-04-10 Институт биологии Коми научного центра Уральского отделения Российской академии наук Средство "экдистерон-80", обладающее кардиопротекторной, адаптогенной, антигипоксической, гастропротекторной, термопротекторной, анаболической и актопротекторной активностью, и способ его производства
US7906159B2 (en) 2008-04-17 2011-03-15 Vivien Chou Herbal compositions and methods for enhancing vital energy and athletic performance
RU2390270C1 (ru) 2009-03-13 2010-05-27 Общество С Ограниченной Ответственностью "Парафарм" Биологически активная добавка к пище
US8343946B2 (en) 2009-07-27 2013-01-01 Thermolife International, Llc Ecdysterone compounds
EP2632474B1 (en) 2010-10-26 2016-08-24 Vasil Petrov Terezov Composition for food supplement and its use for lowering high cholesterol level
FR2983733B1 (fr) 2011-12-13 2017-12-22 Inst Biophytis Sas Phytoecdysones pour leur utilisation dans l'amelioration de la qualite musculaire de mammiferes obeses et/ou sarcopeniques
CN102631577B (zh) 2012-04-03 2013-09-18 刘宪荣 一种治疗溲赤型足底疔的中药洗剂制备方法
CN102631573B (zh) * 2012-04-03 2013-12-25 迟华群 一种治疗溲赤型红丝疔的中药洗剂制备方法
CN102727505A (zh) * 2012-07-09 2012-10-17 中国航天员科研训练中心 红景天苷在防治肌萎缩疾病中的应用
CN102727560B (zh) 2012-07-09 2014-07-09 中国航天员科研训练中心 红景天在预防和治疗肌萎缩疾病中的应用
JP2014015429A (ja) * 2012-07-10 2014-01-30 Kao Corp サテライト細胞分化促進剤
CN103432452A (zh) * 2013-08-22 2013-12-11 韩增禄 一种治疗嗜食辣椒型急性颈部淋巴结炎的中药制备方法

Also Published As

Publication number Publication date
WO2016125025A1 (en) 2016-08-11
KR20180011755A (ko) 2018-02-02
JP6726196B2 (ja) 2020-07-22
JP2018505892A (ja) 2018-03-01
RU2017127509A (ru) 2019-03-04
CA2975497A1 (en) 2016-08-11
US20160220624A1 (en) 2016-08-04
BR112017016497A2 (pt) 2018-04-10
MX384303B (es) 2025-03-12
KR102520312B1 (ko) 2023-04-12
US9700589B2 (en) 2017-07-11
US20170296605A1 (en) 2017-10-19
AU2016214079B2 (en) 2021-04-01
EP3253399B1 (en) 2021-10-13
RU2730853C2 (ru) 2020-08-26
CN107624069A (zh) 2018-01-23
CA2975497C (en) 2023-08-01
EP3253399A1 (en) 2017-12-13
AU2016214079A1 (en) 2017-08-17
BR112017016497B1 (pt) 2021-03-30
CO2017007874A2 (es) 2017-10-20
US10258658B2 (en) 2019-04-16
RU2017127509A3 (es) 2019-08-29

Similar Documents

Publication Publication Date Title
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
MX2015011753A (es) Metodos para tratar cancer de vegija.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
CL2015002191A1 (es) Composición antifúngica tópica para el tratamiento de onicomicosis.
UY35823A (es) Profármacos de antagonista de nmda